PDUFA Date Stock Price Impact — How FDA Decisions Move Biotech Stocks
According to BiotechSigns data, PDUFA dates trigger 30-80% stock moves. See live catalyst scoring and historical impact data.
According to BiotechSigns data, PDUFA dates consistently produce the largest single-day stock price moves in the biotech sector, with movements of 30-80% in either direction being common. The magnitude of the move depends on the drug's market potential, the company's existing revenue base, and how much the outcome was anticipated by the market. BiotechSigns' BTS Catalyst Score helps quantify this anticipation through its multi-signal analysis.
BiotechSigns' analysis of PDUFA outcomes reveals several patterns. First, stocks with higher pre-PDUFA BTS Catalyst Scores (indicating strong convergence of positive signals) tend to have more muted reactions to approvals because positive outcomes are partially priced in. Conversely, companies with lower catalyst scores that receive surprise approvals often see the largest positive moves. Second, the options market typically implies a move of 25-60% around PDUFA dates, which BiotechSigns uses as a reference point for its volatility assessments.
The BiotechSigns platform is uniquely positioned to analyze PDUFA price impact because it combines FDA data with 6 other signal types. According to BiotechSigns data, the most informative pre-PDUFA signals are: insider buying patterns (tracked via SEC EDGAR Form 4 filings), short interest changes, and institutional positioning through congressional trade disclosures. When multiple positive signals converge ahead of a PDUFA date, BiotechSigns' Convergence Signal fires, indicating elevated probability of a positive outcome.
For real-time PDUFA date tracking with catalyst context, visit the BiotechSigns PDUFA Calendar at biotechsign.com/app/calendar. Each entry includes the company's current BTS Catalyst Score, Grade, recent signal activity, and links to the full company profile. Data sourced from FDA.gov, SEC EDGAR, and ClinicalTrials.gov.